U.S. Congressmen Call On China To Bring To Justice Those Who Deliberately Adulterated Heparin
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Although the case of nearly 150 patients across American hospitals who died after being given heparin that was deliberately adulterated in China two years ago had seemed to fade from front pages and some regulatory radar screens, two U.S. congressmen have been waging a vigil-like campaign for U.S. FDA leaders to press Chinese counterparts to help bring those responsible to justice
You may also be interested in...
Asia Spotlight: U.S. Congressmen Call On FDA Commissioner To Press Investigation Into Adulterated Heparin During Upcoming Trip To China
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at 1PAN_Trial_LP.html"http://pharmasianews.elsevierbi.com/ PAN_Trial_LP.html for a free trial.
Asia Spotlight: U.S. Congressmen Call On FDA Commissioner To Press Investigation Into Adulterated Heparin During Upcoming Trip To China
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at 1PAN_Trial_LP.html"http://pharmasianews.elsevierbi.com/ PAN_Trial_LP.html for a free trial.
U.S. Congressmen Call On FDA Commissioner To Press Investigation Into Adulterated Heparin During Upcoming Trip To China
BEIJING - Calling the blood thinner heparin that was deliberately adulterated in China and exported to American hospitals the worst drug supply contamination in history, two U.S. congressmen are urging the commissioner of FDA to seek resolution of the case during an upcoming trip to China